Centers for Disease Control and Prevention US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-Associated Hospitalizations | RFA IP 15 00203CONT17

Opportunity Information: Apply for RFA IP 15 00203CONT17

The grant opportunity titled "Centers for Disease Control and Prevention US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-Associated Hospitalizations" is a CDC cooperative agreement continuation focused on maintaining and supporting an existing US-based platform that measures how well influenza vaccines work at preventing severe influenza outcomes that result in hospitalization. The central purpose is to generate reliable, timely estimates of influenza vaccine effectiveness (often abbreviated as VE) specifically against laboratory-confirmed, influenza-associated hospitalizations, which is one of the most important indicators of severe disease burden and vaccine impact in the population.

This notice is not an open competition. It is explicitly a continuation award, meaning funding is intended only for organizations that previously received an award under the earlier solicitation RFA-IP-15-002. In practice, that makes eligibility narrowly limited to prior grantees already participating in this established platform. The CDC is using the continuation mechanism to keep the existing network operating rather than to create a new program or bring in new sites. The opportunity is administered through CDC ERA, uses a cooperative agreement as the funding instrument, and is categorized under health-related activities. Cooperative agreements typically indicate substantial involvement by the CDC during the period of performance, such as collaboration on study protocols, data standards, analytic approaches, and reporting timelines, rather than a hands-off grant model.

The programmatic emphasis is on vaccine effectiveness measurement using laboratory confirmation, which generally implies systematic enrollment or identification of hospitalized patients with acute respiratory illness, standardized influenza testing (for example, molecular assays), and consistent case definitions and data collection across participating sites. By focusing on hospitalization endpoints rather than outpatient illness alone, the platform supports decision-making around vaccine policy, strain selection context, and assessment of vaccine performance in high-risk groups, including older adults, young children, pregnant people, and individuals with underlying medical conditions. The results from such platforms are commonly used to inform public health messaging during flu seasons, support estimates of disease burden prevented by vaccination, and guide improvements in vaccine development and vaccination strategies.

From the source details provided, the funding opportunity number is RFA IP 15 00203CONT17, and the opportunity category is labeled "Continuation." The CFDA numbers listed are 93.083 and 93.185, which correspond to CDC assistance programs that can cover influenza and immunization-related public health work. The expected number of awards is 10, consistent with sustaining a multi-site network rather than supporting a single awardee. The award ceiling is shown as 0, which often indicates that a fixed maximum amount is not specified in the public synopsis, that the amount may be determined by prior-year funding levels, or that budgets are negotiated within the continuation framework for already-funded partners.

Key administrative dates in the synopsis include a creation date of 2017-02-12 and an original closing date of 2017-04-03. Because the notice is targeted to existing awardees, these dates function more like internal deadlines for continuation application materials, progress reporting, and budget submissions rather than a broad public application window. The eligible applicants field is listed as "Others," but the description clarifies the practical constraint: only prior recipients under RFA-IP-15-002 are intended to receive continuation funding.

In short, this opportunity is designed to keep a CDC-coordinated, US multi-site influenza hospitalization vaccine effectiveness platform operating, ensuring continuity of methods and data streams that allow the CDC to monitor how well seasonal influenza vaccines prevent lab-confirmed influenza-associated hospitalizations across different seasons and populations. It supports ongoing surveillance-quality research infrastructure and collaboration rather than launching a new, open call for proposals.

• The Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Centers for Disease Control and Prevention US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-Associated Hospitalizations" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.083, 93.185.
• This funding opportunity was created on 2017-02-12.
• Applicants must submit their applications by 2017-04-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Others.

Apply for RFA IP 15 00203CONT17

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: